消癌平注射液联合化疗治疗晚期非小细胞肺癌的Meta分析

目的]本研究旨在从循证医学角度系统评价消癌平注射液联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法]计算机检索截止至2018年5月已经发表在Cochrane Library、PubMed、EMBASE、中国期刊全文数据库(CNKI)、万方期刊数据库、维普资讯中文期刊服务平台(VIP)中的文献,纳入消癌平注射液联合化疗治疗NSCLC的临床随机对照试验。对纳入的研究采用"偏倚风险评估工具"进行文献质量评价。提取研究特征、方法和结果的数据,运用Review Manager 5.3软件进行分析,并检验发表偏倚。结果]共纳入文献26篇,病例1 783例。结果显示,与单纯化疗组相比,消癌平注射液联合化疗能提高治疗的总有效率RR=1.30,95%CI(1.16,1.46),P0.000 01]、疾病控制率RR=1.17,95%CI(1.10,1.23),P0.000 01)]、生活质量RR=2.16,95%CI(1.80,2.61),P0.000 01],并能减少不良反应的发生。结论]消癌平注射液能提高晚期NSCLC患者化疗疗效,改善生活质量,减轻不良反应。

Meta-analysis of Xiaoaiping Injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer

Objective] This study systematically evaluated the clinical efficacy and adverse reactions of Xiaoaiping Injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) from the perspective of evidence-based medicine.Methods] The literatures as of May 2018 were published in the Cochrane Library,PubMed,EMBASE,CNKI,Wanfang data,and VIP. The randomized controlled trial of Xiaoaiping injection combined with chemotherapy in the treatment of non-small cell lung cancer was included. For the included studies,the "The Cochrane Collaboration''s tool for assessing risk of bias" was used for literature quality evaluation. Data on study characteristics,methods,and results were extracted,analyzed using RevMan 5.3,and published bias was examined.Results] A total of 26 articles were included,and a total of 1 783 cases were included. As a result,compared with the chemotherapy alone group,Xiaoaiping Injection combined with chemotherapy can improve the total effective rate of patients (RR=1.30,95% CI1.16,1.46],P<0.000 01),disease control rate (RR=1.17,95% CI1.10,1.23],P<0.000 01),quality of life (RR=2.16,95% CI1.80,2.61],P<0.00001),and reduced the occurrence of adverse reactions.Conclusion] Xiaoaiping Injection can improve the efficacy of chemotherapy in patients with advanced non-small cell lung cancer,improve the quality of life and reduce adverse reactions.